Other studies have shown that the progression of sarcopenia involves impaired mitochondrial quality, which is marked by the reduction or loss of OPA1, MFN2, and DRP1 expression (Favaro et al., 2019; Sebastian et al., 2016; Tezze et al., 2017). This evidence concerns the gene MFN2 and sarcopenia.